echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tengsheng Biopharma's Phase I clinical trial of HIV drug BRII-732 suspended by FDA

    Tengsheng Biopharma's Phase I clinical trial of HIV drug BRII-732 suspended by FDA

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: info

    On December 12, Tengsheng Biopharmaceutical announced that it had received a notice from the US FDA to suspend the Phase I clinical study evaluating the safety of BRII-732 in healthy subjects


    The FDA's suspension is mainly based on clinical studies related to Merck's drug islatravir (nucleoside reverse transcriptase translocation inhibitor)


    On November 18, 2021, Merck announced the termination of Phase II IMAGINE-DR due to the observed decrease in total lymphocyte and CD4+ T cell counts in subjects randomized to receive islatravir + MK-8507 (a non-nucleoside reverse transcriptase inhibitor) (MK-8591-013) Research


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.